Wall Street's Wildest Stock Showdowns: Bulls vs. Bears!

Wall Street's Most Polarizing Shitshows: 3 Stocks Where Bulls and Bears Are Throwing Hands (and Maybe Some Feces) — Fresh Edition, October 1, 2026[1]

Futures mixed—Dow flatter than a day-old pancake, Nasdaq still riding the AI hype train like it's 2023 all over again, crude oil bouncing around like a drunk on a pogo stick. Last edition's Bitcoin miner AI pivots, zinc battery cash bonfires, and genetic testing billing nightmares? Old news. These three fresh brawlers have the Street more divided than a Reddit thread on pineapple pizza. Sky-high short interest (one flirting with 50%+ of float, others in the mid-30s with days-to-cover that scream "squeeze or get squeezed"), robot delivery drama, cancer drug revenue rockets, and daily-deals nostalgia vs. irrelevance. Fresh filings, guidance tweaks, and hedge fund chatter only—no reruns. Bulls smell squeezes and structural tailwinds; bears see dilution, execution flops, and cash furnaces. First-principles hammer incoming.[2]

1. Serve Robotics (SERV) – Delivery Bot Darling or Uber Ghosted Cash Burner?

SERV carries hefty short interest around 37-38% of float (recently ~32M shares short, days-to-cover ~11.5), with borrow fees spiking as high as 57% in spots—polarization on its robot army versus partnership headaches and guidance cuts.[2]

Bull Case (The "Robot Swarm and AI Delivery Future Crew")
Bulls highlight the robotics/AI angle for last-mile delivery, expanding deployments with partners like White Castle and DoorDash, heavy call option buying signaling bullish bets, institutional accumulation (BlackRock adding shares), and a massive addressable market as labor shortages persist. Recent cost discipline (lowered opex and capex guidance) could preserve the $240M+ cash runway, with utilization ramps potentially driving software monetization and a short squeeze on any positive contract news or volume beats.[3]

Bear Case (The "Uber Split, Revenue Gutted, and Dilution Doom Crew")
Bears hammer the recent 2026 revenue guidance slash to $9-10M (from $26M) after the Uber Eats relationship soured over "fundamental disagreements," persistent losses, insider selling, and questions on whether robot economics scale without endless capital raises. Competition from bigger players and execution risks in a capital-intensive space keep shorts comfortable despite the hype.[4]

My First-Principles Take: Value in autonomous delivery accrues to players with proprietary hardware/software edges, dense deployment networks, and sticky high-utilization contracts that cover capex and deliver positive unit economics—raw compute and sensors matter less than real-world reliability and cost-per-delivery beats versus human drivers. SERV has genuine tailwinds from labor shortages and AI/robotics momentum plus cash on hand, but durable profits only come if it rebuilds key partnerships, ramps utilization without quality issues or delays, and converts deployments into recurring revenue without dilution. The robot bet is directionally sound amid automation waves, yet it's execution-heavy and partner-dependent, prone to funding shocks or tech hiccups. At these short levels, volatility rocket fuel—catalysts roast bears; stumbles feed the fire. Size like you've got a margin call incoming.

2. ImmunityBio (IBRX) – Anktiva Cancer Rocket or Biotech Cash Sink with Moonshot Dreams?

IBRX sports notable short interest around 32%, reflecting deep splits on its immunotherapy platform versus cash burn and clinical risks, even as revenue surges.[5]

Bull Case (The "Anktiva Revenue Explosion and Label Expansion Crew")
Bulls point to record Q2 net product revenue of $50.7M (up 92% YoY), first-half jump of 121%, international deals (Accord Healthcare for 30 markets, UAE authorization), hedge fund love (named top holding with massive market opportunity estimates for bladder cancer and beyond), upcoming FDA decisions (PDUFA Jan 2027 for papillary disease expansion), new patents, BCG supply deals, and pipeline momentum into sepsis and lung cancer. Strong Buy analyst targets and potential short squeeze on positive catalysts.[6]

Bear Case (The "Still Unprofitable, Lawsuit Shadows, and Trial Risks Crew")
Bears cite ongoing net losses, securities lawsuit overhang, dilution history, high clinical/development costs, and skepticism that Anktiva's bladder cancer success translates to broader indications or sustained profitability amid competition and regulatory hurdles. Shorts bet the hype outpaces near-term cash flow reality.[7]

My First-Principles Take: Biotech value accrues to therapies with clear clinical differentiation (efficacy/safety vs. standards), scalable manufacturing, and expanding indications that unlock larger markets—immune activation via IL-15 pathways can be powerful if it delivers durable responses without toxicity walls. IBRX has real tailwinds from Anktiva's launch traction, international access, and policy/partner support, but durable profits only come if label expansions hit, revenue scales faster than burn, and pipeline assets validate without setbacks. The immuno-oncology bet is directionally explosive on unmet needs, yet it's capital-intensive, regulatory-sensitive, and competition-prone. At these short levels, volatility grenade—positive data or approvals roast shorts; misses feed the fire. High-risk, high-reward for the bold.

3. Groupon (GRPN) – Daily Deals Comeback King or Irrelevant Relic in the Amazon Era?

GRPN boasts sky-high short interest around 52% of float (~13M shares short, days-to-cover ~14), with recent increases signaling intense disagreement on its turnaround versus structural decline.[8]

Bull Case (The "Local Commerce Pivot and AI Builder Momentum Crew")
Bulls highlight potential in local experiences/deals amid post-pandemic recovery, AI tools (new "AI Builder Pack" launch), cost controls, institutional ownership (~94%), and short squeeze potential given the extreme short ratio and any positive volume or guidance surprises. Turnaround narratives around merchant tools and personalization could reignite growth.[9]

Bear Case (The "Competition Crushing, Revenue Stagnation, and Relevance Fade Crew")
Bears point to persistent challenges from bigger platforms (Google, Amazon, specialized apps), questionable long-term viability of the coupon model, recent short interest builds, and doubts on execution in a crowded space. Valuation skepticism and macro consumer spending worries keep bears loaded.[10]

My First-Principles Take: Marketplace value accrues to platforms with strong network effects, differentiated local inventory, and tools that drive merchant ROI and repeat user engagement—simple deal aggregation commoditizes quickly without unique data or tech moats. GRPN has tailwinds from local commerce demand and AI enhancements plus a clean-ish balance sheet relative to history, but durable profits only come if it differentiates beyond coupons, grows active merchants/users profitably, and fends off giants without endless marketing spend. The local deals bet is directionally plausible in fragmented markets, yet it's competitive and execution-sensitive. At these short levels, volatility powder keg—beat-and-raise catalysts roast bears; misses feed the fire. Do your homework, degenerates.

There you have it—three fresh showdowns proving disagreement is the market's favorite stimulant. Do your own damn homework, size like an adult, and remember: the tape stays irrational longer than your margin account can breathe. Sources pulled from latest short interest data, filings, and analyst notes as of late September/early October 2026 (Benzinga, company releases, QuiverQuant, etc.). Trade responsibly, you magnificent animals.